Vebreltinib is named as an intervention in 6 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Avistone Biotechnology Co., Ltd (1). The most-studied condition is Non-Small-Cell Lung Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
NCT06574347 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
|
Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | China |
|
Vebreltinib for Advanced or Metastatic CCS
NCT07153887 · ClinicalTrials.gov ↗ · Clear Cell Sarcoma (CCS)
|
Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC
|
Phase 1/2 | Recruiting | Peking University Cancer Hospital & Institute | China |
|
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
NCT07655622 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
|
Phase 1/2 | Recruiting | Second Affiliated Hospital of Nanchang University | China |
|
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
NCT07549061 · ClinicalTrials.gov ↗ · Lung Neoplasms
|
Phase 2 | Not yet open | Shanghai Chest Hospital | China |
|
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
NCT06827145 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
|
Phase 2 | Active, closed | National Cancer Center, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Avistone Biotechnology Co., Ltd. | 1 |
| National Cancer Center, China | 1 |
| Second Affiliated Hospital of Nanchang University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Shanghai Chest Hospital | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 4 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our China register name Vebreltinib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 6 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Avistone Biotechnology Co., Ltd (1), National Cancer Center, China (1), Second Affiliated Hospital of Nanchang University (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vebreltinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vebreltinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vebreltinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.